Steiner R W, Coggins C, Carvalho A C
Am J Hematol. 1979;7(2):107-17. doi: 10.1002/ajh.2830070203.
Modified Ivy bleeding time (template) and platelet aggregation to ADP, epinephrine, and collagen were studied in 26 uremic patients who had not recently ingested anti-platelet drugs. Regardless of the aggregating agent used, the abnormalities in platelet aggregation were often mild, even with advanced uremia, and frequently less severe than the effects of common anti-platelet drugs. The inhibition of collagen-induced aggregation was significantly correlated with both increased bleeding time and blood urea nitrogen. Platelet aggregation was not discriminative between clinically bleeding and non-bleeding groups of patients, but the bleeding time was helpful in this regard. In certain cases, the aggregometric patterns differed between drug-induced and uremic thrombocytopathies. Platelet aggregometry appears to be of little help clinically in assessing the severity of the uremic bleeding diathesis.
对26例近期未服用抗血小板药物的尿毒症患者进行了改良艾维出血时间(模板法)以及血小板对二磷酸腺苷、肾上腺素和胶原的聚集功能研究。无论使用何种聚集诱导剂,即使是晚期尿毒症患者,血小板聚集异常通常也较轻微,且往往不如常见抗血小板药物的作用严重。胶原诱导的聚集抑制与出血时间延长和血尿素氮均显著相关。血小板聚集功能在区分临床出血和未出血的患者组方面并无鉴别意义,但出血时间在这方面有帮助。在某些情况下,药物诱导的血小板病和尿毒症血小板病的聚集模式有所不同。血小板聚集试验在临床上评估尿毒症出血素质的严重程度似乎帮助不大。